SG11201603166UA - Method - Google Patents

Method

Info

Publication number
SG11201603166UA
SG11201603166UA SG11201603166UA SG11201603166UA SG11201603166UA SG 11201603166U A SG11201603166U A SG 11201603166UA SG 11201603166U A SG11201603166U A SG 11201603166UA SG 11201603166U A SG11201603166U A SG 11201603166UA SG 11201603166U A SG11201603166U A SG 11201603166UA
Authority
SG
Singapore
Application number
SG11201603166UA
Inventor
Luigi Naldini
Bernhard Rudolf Gentner
Erika Zonari
Francesco Boccalatte
Original Assignee
Ospedale San Raffaele Srl
Fond Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318830A external-priority patent/GB201318830D0/en
Priority claimed from GB201409067A external-priority patent/GB201409067D0/en
Application filed by Ospedale San Raffaele Srl, Fond Telethon filed Critical Ospedale San Raffaele Srl
Publication of SG11201603166UA publication Critical patent/SG11201603166UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
SG11201603166UA 2013-10-24 2014-10-24 Method SG11201603166UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201318830A GB201318830D0 (en) 2013-10-24 2013-10-24 Method
GB201409067A GB201409067D0 (en) 2014-05-21 2014-05-21 Method
PCT/IB2014/065594 WO2015059674A1 (en) 2013-10-24 2014-10-24 Method

Publications (1)

Publication Number Publication Date
SG11201603166UA true SG11201603166UA (en) 2016-05-30

Family

ID=52007237

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603166UA SG11201603166UA (en) 2013-10-24 2014-10-24 Method

Country Status (11)

Country Link
US (2) US10617721B2 (en)
EP (2) EP3613859A1 (en)
JP (2) JP6691048B2 (en)
KR (1) KR20160075676A (en)
CN (1) CN106062201B (en)
AU (1) AU2014338555B2 (en)
CA (1) CA2927712A1 (en)
CY (1) CY1122612T1 (en)
ES (1) ES2747951T3 (en)
SG (1) SG11201603166UA (en)
WO (1) WO2015059674A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102011532B1 (en) * 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. Compounds for improved viral transduction
GB201407322D0 (en) * 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
CN108883136A (en) * 2016-02-12 2018-11-23 蓝鸟生物公司 VCN enhancer combination object and its application method
EP3526319A4 (en) 2016-10-14 2020-07-29 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
WO2018106610A1 (en) * 2016-12-05 2018-06-14 The Regents Of The University Of California Immunomagnetic bead-based method to enrich stem cells from whole hematopoietic tissue
WO2018136434A1 (en) 2017-01-17 2018-07-26 Children's Medical Center Corporation Compositions and methods for diagnosing and treating peroxisomal diseases
AU2018210853B2 (en) 2017-01-17 2023-09-28 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
WO2019046815A1 (en) * 2017-08-31 2019-03-07 Poseida Therapeutics, Inc. Transposon system and methods of use
FR3074189A1 (en) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris METHOD OF GENERATING HEMATOPOIETIC STEM CELL GRAFTS
WO2021067613A1 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating amyotrophic lateral sclerosis
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
WO1993025216A1 (en) 1992-06-08 1993-12-23 Becton, Dickinson And Company Human primitive stem cells
DE69426948T2 (en) 1993-02-09 2001-10-11 Becton Dickinson And Co., Franklin Lakes Automatic determination of the cell line of severe leukaemias by flow cytometry
US6555324B1 (en) 1993-11-04 2003-04-29 Becton Dickinson & Company Method to distinguish hematopoietic progenitor cells
EP0662512A3 (en) 1993-12-20 1997-01-15 Becton Dickinson Co Human hematopoietic stem cells.
DE69531432T2 (en) 1994-09-23 2004-07-29 Becton Dickinson And Co. Method of distinguishing granulomoncytic progenitors in a population of CD34 + cells
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2263154A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998015615A1 (en) 1996-10-10 1998-04-16 Duke University Method of producing a thymic microenvironment that supports the development of dendritic cells
CN1195863C (en) 1996-10-17 2005-04-06 牛津生物医学（英国）有限公司 Retroviral vectors
CA2219869A1 (en) 1997-10-31 1999-04-30 Hsc Research And Development Limited Partnership Human cd-34 hematopoietic stem cells
US6006633A (en) 1998-07-08 1999-12-28 The Stanley Works Pliers (1)
AU2036700A (en) 1998-12-04 2000-06-26 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
EP1135465A2 (en) 1998-12-04 2001-09-26 Naval Medical Research Center Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells
CA2877233A1 (en) 1999-01-19 2000-07-27 Lola M. Reid Human liver progenitors
CA2382832C (en) * 1999-10-12 2012-06-26 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20020159984A1 (en) 1999-11-12 2002-10-31 Quality Biological, Inc. Cultivation of cells for long term engraftment
US6849454B2 (en) * 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
WO2001066150A2 (en) * 2000-03-07 2001-09-13 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
NL1017973C2 (en) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Design.
US20040023324A1 (en) 2000-08-25 2004-02-05 Seiji Sakano Stem cell culture medium and culture method by using the same
CA2438153C (en) * 2001-02-14 2015-06-02 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP1463821A4 (en) * 2001-12-21 2006-05-31 Us Health In increasing gene transfer efficiency by pre-incubation with endothelial cells
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
CA2476553A1 (en) 2002-02-13 2003-08-21 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004072264A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof
CA2556018A1 (en) 2004-02-11 2005-09-09 Aldagen, Inc. Stem cell populations and methods of use
KR100561079B1 (en) 2004-03-09 2006-03-15 재단법인서울대학교산학협력재단 A method for culturing and proliferating hematopoietic stem cell and progenitor cell by using human endometrial cells
DE602004031283D1 (en) 2004-05-05 2011-03-17 Zorica Becker-Kojic Use of glycoprotein ACA antibodies to obtain or maintain pluripotent non-embryonic stem cells
US20060046268A1 (en) 2004-08-26 2006-03-02 Australian Stem Cell Centre Ltd. Diagnosis of anemia and optimizing treatment for heart repair
JP2008504821A (en) 2004-07-01 2008-02-21 バイレクシス コーポレイション Vector packaging cell line
JP4706208B2 (en) 2004-08-27 2011-06-22 株式会社アイル Method for producing hematopoietic stem cells
KR20070103431A (en) 2005-01-27 2007-10-23 리제네텍 인코포레이티드 Method of providing readily available cellular material derived from cord blood, and a composition thereof
CN101166541A (en) 2005-02-28 2008-04-23 雷格内泰克公司 Method and composition for repairing heart tissue
WO2006093857A2 (en) 2005-02-28 2006-09-08 Regenetech, Inc. Method of providing readily available cellular material derived from peripheral blood and a composition thereof
WO2006093881A2 (en) 2005-02-28 2006-09-08 Regenetech, Inc. Method and composition for repairing epithelial and other cells and tissue
KR20070111533A (en) 2005-02-28 2007-11-21 리제네텍 인코포레이티드 Method and composition for treating diabetes
FR2891551A1 (en) 2005-10-03 2007-04-06 Jaafari Assia El Production of dendritic cells from a hematopoietic progenitor through culture, comprises collecting hematopoietic cell strains, subjecting the cells to a gradient density and cultivating the cell population in a medium
KR100702862B1 (en) 2005-12-01 2007-04-03 메디포스트(주) / Method for ex vivo growth and expansion of hematopoietic stem/progenitor cells using umbilical cord blood-derived mesenchymal stem cells as a cell feeder layer
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
KR100773253B1 (en) 2007-03-26 2007-11-05 주식회사 알앤엘바이오 Method for culturing and proliferating of hematopoietic cells through co-culture with adult stem cells
WO2008136670A2 (en) 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
WO2008136656A1 (en) * 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
EP2218716B1 (en) 2007-12-06 2016-11-16 Nissan Chemical Industries, Ltd. Method for amplifying hematopoietic stem cells using heterocyclic compound
US20090191164A1 (en) 2008-01-15 2009-07-30 Ravindra Majeti Human hematopoietic multipotent progenitor cells
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
AR071353A1 (en) 2009-02-20 2010-06-16 Regenetech Inc METHOD AND COMPOSITION TO REPAIR CARDIAC FABRIC
JP5748653B2 (en) 2009-04-10 2015-07-15 協和発酵キリン株式会社 Hematological tumor therapy using anti-TIM-3 antibody
SG175839A1 (en) 2009-04-30 2011-12-29 San Raffaele Centro Fond Gene vector
CN101706507B (en) 2009-07-27 2013-05-01 浙江大学 Application of anti-human CD45RA monoclonal antibody marked by fluorescein isothiocyanate
CN101831434B (en) 2009-07-27 2012-05-09 浙江大学 Anti-human CD45RA rat immune globulin variable region gene and application
CN101735979B (en) 2009-12-31 2014-04-30 浙江中赢控股集团有限公司 Method for in vitro amplification of hemopoietic stem cells and precursor cells
KR20120006386A (en) 2010-07-12 2012-01-18 (주)마리아 바이오텍 Stem cell derived from first trimester placenta and cellular therapeutic agents comprising the same
US9290739B2 (en) 2010-09-08 2016-03-22 Kang Stem Biotech Co., Ltd. Equine amniotic fluid-derived multipotent stem cells and a method for producing the same
JP2014504862A (en) 2011-01-03 2014-02-27 ブルーバード バイオ， インコーポレイテッド Methods for enhancing delivery of cells transduced with genes
CN102220282A (en) 2011-04-26 2011-10-19 广东省人民医院 Method for separating leukemia stem cells from leukemia cell strain
KR20130028294A (en) 2011-09-09 2013-03-19 주식회사 강스템홀딩스 Isolation and characterization of canine wharton's jelly-derived mesenchymal stem cells
US9012215B2 (en) 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
KR102011532B1 (en) * 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. Compounds for improved viral transduction
KR101906156B1 (en) 2011-11-22 2018-10-12 주식회사 강스템바이오텍 Equine Amniotic Membrane-Derived Mesenchymal Stem Cells
US9771555B2 (en) 2011-12-06 2017-09-26 Kang Stem Biotech, Co., LTD. Canine amniotic membrane-derived multipotent stem cells
CN103018463B (en) 2012-12-20 2015-08-05 北京大学人民医院 Detect kit and the application thereof of B-lineage Acute Lymphocyte Leukemia associated immunophenotype

Also Published As

Publication number Publication date
WO2015059674A1 (en) 2015-04-30
KR20160075676A (en) 2016-06-29
EP3613859A1 (en) 2020-02-26
ES2747951T3 (en) 2020-03-12
US20200338131A1 (en) 2020-10-29
AU2014338555B2 (en) 2019-10-10
US20160256492A1 (en) 2016-09-08
EP3060670A1 (en) 2016-08-31
EP3060670B1 (en) 2019-07-10
JP2016539659A (en) 2016-12-22
US10617721B2 (en) 2020-04-14
JP2020124200A (en) 2020-08-20
CY1122612T1 (en) 2021-03-12
JP6691048B2 (en) 2020-04-28
CN106062201B (en) 2020-11-06
CN106062201A (en) 2016-10-26
CA2927712A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
GB201314695D0 (en) Method
GB201318465D0 (en) Method
GB201320351D0 (en) Method
GB201309057D0 (en) Method
SG11201603166UA (en) Method
GB201316744D0 (en) Method
GB201316849D0 (en) Method
GB201309928D0 (en) Method
GB201301857D0 (en) Method
GB201313249D0 (en) Method
GB201309654D0 (en) Method
GB201305714D0 (en) Method
GB201301233D0 (en) Method
GB201300409D0 (en) Method
GB201311385D0 (en) Method
GB201301094D0 (en) Method
GB201314054D0 (en) Method
GB201312609D0 (en) Method
GB201311389D0 (en) Method
GB201322768D0 (en) Method
GB201319361D0 (en) Method
GB201318830D0 (en) Method
GB201318490D0 (en) Method
GB201317970D0 (en) Method
GB201317826D0 (en) Method